3.47
Adc Therapeutics Sa Borsa (ADCT) Ultime notizie
Bank of America Corp DE Sells 1,206,696 Shares of ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
Adc Therapeutics SA (NYSE: ADCT) Jumps 2.28%, Turning Investors Away - Stocksregister
ADC Therapeutics SA (NYSE:ADCT) Stock Position Boosted by Deutsche Bank AG - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire
Bank of America Corp DE Has $2.57 Million Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Astellas and Evopoint sign ADC licensing deal - Pharmaceutical Technology
Woodline Partners LP Takes Position in ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
Shareholders Will Likely Find ADC Therapeutics SA's (NYSE:ADCT) CEO Compensation Acceptable - simplywall.st
BNP Paribas Financial Markets Takes $1.43 Million Position in ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
Equities Analysts Set Expectations for ADCT FY2025 Earnings - MarketBeat
Antibody Drug Conjugates Market will reach 11.5 Billion USD by 2032 - newstrail.com
ADC Therapeutics signals data catalysts ahead with ZYNLONTA combinations, aims for regulatory milestones through 2025 - MSN
BNP Paribas Financial Markets Purchases Shares of 716,668 ADC Therapeutics SA (NYSE:ADCT) - Defense World
FY2025 EPS Estimates for ADCT Increased by Cantor Fitzgerald - Defense World
Orbimed Advisors LLC Acquires 1,434,650 Shares of ADC Therapeutics SA (NYSE:ADCT) - MarketBeat
ADC Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update - Nasdaq
Analysts Are Upgrading ADC Therapeutics SA (NYSE:ADCT) After Its Latest Results - simplywall.st
Royal Bank of Canada Reaffirms “Outperform” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics patents new anti-NaPi2b conjugates - BioWorld MedTech
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates - MSN
ADC Therapeutics (ADCT) Receives Reiterated Outperform Rating fr - GuruFocus
ADC Therapeutics presents new anti-ASCT2 conjugates - BioWorld MedTech
ADC Therapeutics SA (NYSE:ADCT) Q1 2025 Earnings Call Transcript - MSN
ADC Therapeutics to Present at Upcoming Investor Conferences - GuruFocus
ADCT Reveals Promising LOTIS-7 Trial Data for ZYNLONTA | ADCT St - GuruFocus
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data - Clinical Trials Arena
ADC Therapeutics reports high response in lymphoma trial By Investing.com - Investing.com Canada
ADC Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat
ADCT stock touches 52-week low at $1.66 amid market challenges - MSN
ADC Therapeutics stock plunges 36% amid Zynlonta data release - MSN
ADC Therapeutics SA 2025 Q1ResultsEarnings Call Presentation (NYSE:ADCT) - Seeking Alpha
ADC Therapeutics SA reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : ADC Therapeutics SA, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
ADC Therapeutics Reports First Quarter 2025 Financial Results - TradingView
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) - GuruFocus
ADC Therapeutics reports high response in lymphoma trial - Investing.com
ADC Therapeutics Announces Presentation of LOTIS-7 Clinical Trial Data at the European Hematology Association 2025 Congress (EHA2025) and the 18th International Conference on Malignant Lymphoma (ICML) – Company AnnouncementFT.com - Financial Times
What To Expect From ADC Therapeutics SA (ADCT) Q1 2025 Earnings - GuruFocus
Wells Fargo & Company MN Increases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.
Barclays PLC Purchases 13,756 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics to Host First Quarter 2025 Financial Results Conference Call on May 14, 2025 - BioSpace
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):